Stay updated on Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check77 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase II trial involving pembrolizumab for glioblastoma, while adding new identifiers and procedural details related to glioblastoma treatment, including radiation therapy and the drug temozolomide.SummaryDifference46%
- Check84 days agoChange DetectedThe page has been updated to reflect a new phase II study of Pembrolizumab in treating glioblastoma, with revised dates and definitions for key study metrics, including overall survival and disease progression assessments.SummaryDifference10%
Stay in the know with updates to Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.